Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lars Moller-Pedersen"'
Autor:
Catherine Chassagne-Clément, Marie Maerevoet, Clémentine Sarkozy, Dolores Caballero, Lars Moller Pedersen, Hervé Ghesquières, Sirpa Leppä, Gilles Salles, Richard Delarue, Christophe Fermé, John F. Seymour, Maria Gomes da Silva, Christiane Mounier
Publikováno v:
Blood. 123:2740-2742
To the editor: Follicular lymphoma is typically a disseminated disease with frequent bone marrow infiltration at the time of diagnosis,[1][1] but only a few patients manifest detectable circulating peripheral blood lymphoma cells (CLC).[2][2][⇓][3]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f90a39ed86546e5d7ca3e0d5ce7e433b
https://doi.org/10.1182/blood-2014-02-553693
https://doi.org/10.1182/blood-2014-02-553693
Autor:
Mats Jerkeman, Lars Moller Pedersen, Riku Louhimo, Øystein Fluge, Marja-Liisa Karjalainen-Lindsberg, Ville Rantanen, Satu Koivula, Minna Taskinen, Jan Delabie, Sampsa Hautaniemi, Mikael Eriksson, Magnus Björkholm, Sirpa Leppä, Harald Holte, Karin Fjordén, Ping Chen
Publikováno v:
PLoS ONE
Taskinen, M, Louhimo, R, Koivula, S, Chen, P, Rantanen, V, Holte, H, Delabie, J, Karjalainen-Lindsberg, M L, Bjorkholm, M, Fluge, O, Pedersen, L M, Fjorden, K, Jerkeman, M, Eriksson, M, Hautaniemi, S & Leppa, S 2014, ' Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma ', P L o S One, vol. 9, no. 3, e91031 . https://doi.org/10.1371/journal.pone.0091031
PLoS ONE, Vol 9, Iss 3, p e91031 (2014)
PLoS ONE; 9(3), no e91031 (2014)
Taskinen, M, Louhimo, R, Koivula, S, Chen, P, Rantanen, V, Holte, H, Delabie, J, Karjalainen-Lindsberg, M L, Bjorkholm, M, Fluge, O, Pedersen, L M, Fjorden, K, Jerkeman, M, Eriksson, M, Hautaniemi, S & Leppa, S 2014, ' Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma ', P L o S One, vol. 9, no. 3, e91031 . https://doi.org/10.1371/journal.pone.0091031
PLoS ONE, Vol 9, Iss 3, p e91031 (2014)
PLoS ONE; 9(3), no e91031 (2014)
Background: Despite improved survival for the patients with diffuse large B-cell lymphoma (DLBCL), the prognosis after relapse is poor. The aim was to identify molecular events that contribute to relapse and treatment resistance in DLBCL. Methods: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39dcc7b9b754df4c1cf49a34d60ee38
http://europepmc.org/articles/PMC3953211
http://europepmc.org/articles/PMC3953211
Autor:
Jan Delabie, Mikael Eriksson, Harald Anderson, Alexander Fosså, Lars Moller Pedersen, Arne Kolstad, Martin Erlanson, Sirpa Leppä, Magnus Björkholm, Christer Sundström, Harald Holte, Marie Nordström, Eva Löfvenberg, Bjørn Østenstad, Øystein Fluge, R. Janes, Sirkku Jyrkkiö, Mats Jerkeman, Marja-Liisa Karjalainen-Lindsberg
Publikováno v:
Annals of Oncology; 24(5), pp 1385-1392 (2013)
Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99d8688f991862dbdda1bbeaf26b2253
https://pubmed.ncbi.nlm.nih.gov/23247661
https://pubmed.ncbi.nlm.nih.gov/23247661
Autor:
Ole V. Gadeberg, Bjarne Bach Pedersen, Michael Pedersen, Bo Amdi Pedersen, Francesco d'Amore, Steen Ingeberg, Michael Boe Møller, Paw Jensen, Peter de Nully Brown, Anne Ortved Gang, Stanislaw Pulczynski, Torben Mourits-Andersen, Tobias Wirenfeldt Klausen, Lars Moller-Pedersen
Publikováno v:
Gang, AO, Pedersen, M, D'Amore, F A, Møller-Pedersen, L, Pedersen, BA, Jensen, P, Pedersen, BB, Møller, MB, Gadeberg, O V, Ingeberg, S, Mourits-Andersen, T, Pulczynski, S, Klausen, TW & Brown, P D N 2012, ' A new simplified prognostic index with age cut-off of 70 years for patients with diffuse large B-cell lymphoma. A population-based analysis from the Danish Lymphoma Registry, LYFO ', Blood, vol. 120, no. 21 .
ResearcherID
ResearcherID
Abstract 3651 Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma accounting for 35–40%. Since the 1990s, The International Prognostic Index (IPI) has served as useful tool in daily treatment decision algorithm a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0755287776889e1ce543aaa9a11a188f
https://pure.au.dk/portal/da/publications/a-new-simplified-prognostic-index-with-age-cutoff-of-70-years-for-patients-with-diffuse-large-bcell-lymphoma-a-populationbased-analysis-from-the-danish-lymphoma-registry-lyfo(6478253d-fbd3-4844-8fbc-c9cd8166d7c3).html
https://pure.au.dk/portal/da/publications/a-new-simplified-prognostic-index-with-age-cutoff-of-70-years-for-patients-with-diffuse-large-bcell-lymphoma-a-populationbased-analysis-from-the-danish-lymphoma-registry-lyfo(6478253d-fbd3-4844-8fbc-c9cd8166d7c3).html
Autor:
Karin Rydström, Heidi Nurmi, Sari Riihijärvi, Sirpa Leppä, Magnus Björkholm, Mikael Eriksson, Harald Holte, Lars Moller Pedersen, Øystein Fluge, Mats Jerkeman
Publikováno v:
Riihijärvi, S, Nurmi, H, Holte, H, Björkholm, M, Fluge, O, Pedersen, L M, Rydström, K, Jerkeman, M, Eriksson, M & Leppä, S 2012, ' High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy ', European Journal of Haematology, vol. 89, no. 5, pp. 395-402 . https://doi.org/10.1111/ejh.12005
Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb3fc7eb3b10e92606d1517d19c4098
https://portal.findresearcher.sdu.dk/da/publications/b4ac2d43-7601-4f08-a01b-8d0704884ded
https://portal.findresearcher.sdu.dk/da/publications/b4ac2d43-7601-4f08-a01b-8d0704884ded
Autor:
Ken H. Young, Tina Green, Lars Moller Pedersen, Ole John Nielsen, Ronald S. Go, Mikael Frederiksen, Torben Mourits-Andersen, Carlo Visco, Zijun Y. Xu-Monette, Ole V. Gadeberg, Attilio Orazi, Michael Boe Møller
Publikováno v:
Green, T M, Young, K H, Visco, C, Xu-Monette, Z Y, Orazi, A, Go, R S, Nielsen, O, Gadeberg, O V, Mourits-Andersen, T, Frederiksen, M, Pedersen, L M & Møller, M B 2012, ' Immunohistochemical Double-hit Score Is as Strong Predictor of Outcome In Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide. Doxorubicine, Vincristine, and Prednisone. ', Journal of Clinical Oncology, vol. 30, no. 28, pp. 3460-3467 .
Green, T, Young, K, Visco, C, Xu-Monette, Z, Orazi, A, Go, R, Nielsen, O, Gadeberg, O V, Mourits-Andersen, T, Frederiksen, M, Pedersen, L M & Møller, M B 2012, ' Immunohistochemical Double-Hit Score is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone ', Journal of Clinical Oncology, vol. 30, no. 28, pp. 3460-7 .
Green, T, Young, K, Visco, C, Xu-Monette, Z, Orazi, A, Go, R, Nielsen, O, Gadeberg, O V, Mourits-Andersen, T, Frederiksen, M, Pedersen, L M & Møller, M B 2012, ' Immunohistochemical Double-Hit Score is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone ', Journal of Clinical Oncology, vol. 30, no. 28, pp. 3460-7 .
Purpose Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e33b25fe981ce30f26ba1ccbb8365d64
https://portal.findresearcher.sdu.dk/da/publications/dd625b26-e018-4e85-a320-9bf9c277b80c
https://portal.findresearcher.sdu.dk/da/publications/dd625b26-e018-4e85-a320-9bf9c277b80c
Autor:
Anne Sonet, Lars Moller Pedersen, Corinne Haioun, Alain Delmer, Catherine Sebban, David Belada, Gustavo Milone, Myriam Mendila, Gilles Salles, Olivier Casasnovas, Anton Hagenbeek, Pierre Soubeyran, Luc Xerri, Armando López-Guillermo, Hervé Tilly, Bertrand Coiffier, Sirpa Leppä, Fritz Offner, Jane Estell, Pauline Brice, John F. Seymour, John Catalano, David Simpson, Christophe Fermé, Andrew Lister, Maria Gomes da Silva, Pierre Feugier, Tanin Intragumtornchai, Dolores Caballero, Reda Bouabdallah
Publikováno v:
Lancet, 377(9759), 42-51. Elsevier Limited
Salles, G, Seymour, J F, Offner, F, López-Guillermo, A, Belada, D, Xerri, L, Feugier, P, Bouabdallah, R, Catalano, J V, Brice, P, Caballero, D, Haioun, C, Pedersen, L M, Delmer, A, Simpson, D, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, da Silva, M G, Sebban, C, Lister, A, Estell, J A, Milone, G, Sonet, A, Mendila, M, Coiffier, B & Tilly, H 2011, ' Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial ', Lancet, vol. 377, no. 9759, pp. 42-51 . https://doi.org/10.1016/S0140-6736(10)62175-7
Salles, G, Seymour, J F, Offner, F, López-Guillermo, A, Belada, D, Xerri, L, Feugier, P, Bouabdallah, R, Catalano, J V, Brice, P, Caballero, D, Haioun, C, Pedersen, L M, Delmer, A, Simpson, D, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, da Silva, M G, Sebban, C, Lister, A, Estell, J A, Milone, G, Sonet, A, Mendila, M, Coiffier, B & Tilly, H 2011, ' Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial ', Lancet, vol. 377, no. 9759, pp. 42-51 . https://doi.org/10.1016/S0140-6736(10)62175-7
BACKGROUND: Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3-5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f6be8dba68d252fb280e7e2c04d211
https://pure.amc.nl/en/publications/rituximab-maintenance-for-2-years-in-patients-with-high-tumour-burden-follicular-lymphoma-responding-to-rituximab-plus-chemotherapy-prima-a-phase-3-randomised-controlled-trial(ae9c67ad-641c-450c-9b77-a65da2fdda1e).html
https://pure.amc.nl/en/publications/rituximab-maintenance-for-2-years-in-patients-with-high-tumour-burden-follicular-lymphoma-responding-to-rituximab-plus-chemotherapy-prima-a-phase-3-randomised-controlled-trial(ae9c67ad-641c-450c-9b77-a65da2fdda1e).html
Autor:
Anna Abrahamsson, Alexandra Albertsson Lindblad, Peter de Nully Brown, Stefanie Baumgartner Wennerholm, Lars Moller Pedersen, Francesco d'Amore, Herman Nilsson-Ehle, Paw Jensen, Michael Pedersen, Christian H. Geisler, Mats Jerkeman
Publikováno v:
Blood. 122:4358-4358
Background There is a consensus that younger patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens including high-dose cytarabine, rituximab and high-dose chemotherapy with stem cell support, but the optimizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a5483edca41b9a440bd1281e323ebbb
https://doi.org/10.1182/blood.v122.21.4358.4358
https://doi.org/10.1182/blood.v122.21.4358.4358
Autor:
Christer Sundström, Carin Backlin, Ken H. Young, Marie Wahren-Herlenius, Eva Baecklund, Lars Moller Pedersen, Susanna Brauner, Tina Green, Ingrid E. Lundberg, Björn Löfström, Gunilla Enblad, Michael Boe Møller, Wei Zhou
Publikováno v:
Annals of the Rheumatic Diseases. 72:A40.2-A40
Background and Objectives The risk for lymphoma is increased in many rheumatic conditions. Diffuse Large B-cell Lymphoma (DLBCL) is a common, yet heterogeneous lymphoma subtype and good prognostic biomarkers are warranted. We have previously shown th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f5d13e1a633b43cbacd276b9bf2923d
https://doi.org/10.1136/annrheumdis-2013-203219.27
https://doi.org/10.1136/annrheumdis-2013-203219.27
Autor:
Andrew Lister, Maria Gomes da Silva, Alain Delmer, Anton Hagenbeek, John Catalano, Hervé Tilly, Gilles Salles, Luc Xerri, Tanin Intragumtornchai, Dolores Caballero, Pauline Brice, John F. Seymour, Sirpa Leppä, Pierre Soubeyran, Armando López-Guillermo, Olivier Casasnovas, Pierre Feugier, David Belada, Anne Sonet, Lars Moller Pedersen, David Simpson, Corinne Haioun, Gustavo Milone, Fritz Offner, Jane Estell, Catherine Sebban, Reda Bouabdallah, Christophe Fermé
Publikováno v:
ResearcherID
University of Helsinki
Publons
University of Helsinki
Publons
Abstract 1788 The GELA-sponsored intergroup PRIMA Phase III study was designed to investigate the potential benefit of 2-years of rituximab maintenance in high tumour burden follicular lymphoma patients responding to one of three non-randomised first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c18918e612563b9bf2a48c7ac21af5f
https://doi.org/10.1182/blood.v116.21.1788.1788
https://doi.org/10.1182/blood.v116.21.1788.1788